Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ETSAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, ...
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral ...
In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
A rare association exists between pulmonary hypertension (PH) and hematologic malignancies, particularly AML evolving from MPN. The case study involves a 32-year-old woman with JAK2 mutation-positive ...
In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...
Pulmonary hypertension in kidney transplant recipients is associated with lower graft and patient survival. Pre-existing pulmonary hypertension in kidney transplant recipients (PHTN) is associated ...
Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
Youngstown State University will host an evening with Dr. Rana Awdish, a nationally recognized pulmonary and critical care physician and author, 6 to 7 p.m. April 23 in the recital hall of Bliss Hall.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results